|
|
AGENDA
12th JULY 2008
10:00 AM–1:00
PM Registration
12:00 Noon–1:00
PM Lunch
1:00 PM–1:15
PM
Welcome and Introduction Dr. G.S.
Bhattacharyya & Dr. Mohamed Meshref
1:15 PM–5:30
PM Breast
Cancer Session
Session
Chairpersons
Dr. A.A. Ranade & Dr .Balakrishnan Rajan
1:15 PM–1:45
PM Adjuvant
Therapy Dr. S.H. Advani
• 35897 - Adjuvant ovarian suppression combined with tamoxifen or
anastrozole, alone or in combination with zoledronic acid, in premenopausal
women with hormoneresponsive, stage I and II breast cancer: First efficacy
results from ABCSG-12. M. Gnant, B. Mlineritsch, W. Schippinger, G.
Luschin-Ebengreuth, S. Poestlberger,
C. Menzel, R.Jakesz, E. Kubista, C. Marth, R. Greil, On behalf of the ABCSG
• 30857 - Standard Chemotherapy (CMF or AC) versus capecitabine in early-stage
breast cancer (BC) patients aged 65 and older. Results of CALGB/CTSU 49907
H. B. Muss, D. Berry, C. Cirrincione, M. Theodoulou, A. Mauer, H. Cohen, A.
Partridge,
L. Norton, C.Hudis, E. Winer, North American Breast Cancer Intergroup
1:45–2.30
PM Adjuvant
Therapy Dr. Shyam Aggarwal
• 31397 - Vitamin D (Vit D) deficiency is common at breast cancer
(BC) diagnosis and is associated with a significantly higher risk of distant
recurrence and death in a prospective cohort study of T1-3, N0-1, M0 BC.
P. J. Goodwin, M. Ennis, K. I. Pritchard, J. Koo, N. Hood
• 34423 - tAnGo: A randomized phase III trial of gemcitabine (gem) in
paclitaxel containing, epirubicin/cyclophosphamide based, adjuvant chemotherapy
(CT) for women
C. J.Poole, L. Hiller, H. C. Howard, J. A. Dunn, P. Canney, A. M.
Wardley, M. J. Kennedy, R. E. Coleman, R. C. Leonard, H. M. Earl, tAnGo
trial collaborators
• 31982 - Zoledronic Acid (ZA) preserves bone mineral density
(BMD) in premenopausal women who develop ovarian failure (OF) due to adjuvant
chemotherapy (AdC): First results from CALGB trial 79809
C. L. Shapiro, S. Halabi, G. Gibson, D. J. Weckstein, J. Kirshner, W. M. Sikov,
E. P. Winer, C. A. Hudis, C. Isaacs, D. Weckstein, R. L. Schilsky, E. Paskett
2:30 PM–3:00
PM
Discussion on Adjuvant Therapy
Moderator
Dr. Hemant Malhotra
Panelists
Dr. Dinesh Chandra Doval
Dr. T. Raja
Dr. B.K. Smruti
3:00 –3:15
PM
Tea Break
3.15–3.45 PM
Metastatic Breast Cancer Dr. Maria
Theodoulou
• 34482-Randomised, double-blind, placebo-controlled, phase III
study of bevacizumab with docetaxel or docetaxel with placebo as first-line
therapy for patients with locally recurrent or metastatic breast cancer (mBC):
AVADO
D. Miles, A. Chan, G. Romieu, L. Dirix, J. Cortes, X. Pivot, P. Tomczak, T.
Taran, N. Harbeck , G. Steger
• 36327 - A randomized study of lapatinib alone or in combination
with trastuzumab in heavily pretreated HER2+ metastatic breast cancer
progressing on trastuzumab therapy
J. O'Shaughnessy, K. Blackwell, H. Burstein, A. Storniolo, G. Sledge, J.
Baselga, M. Koehler, S. Laabs, A. Florance, D. Roychowdhury
4.15–4.45 PM
Discussion on Metastatic Breast Cancer
Moderator
Dr. Sudeep Gupta
Panelists
Dr. P. K. Julka
Dr. Ashish Bakshi
Dr. Palanki S Dattatreya
4:45 PM–5:30
PM
Case Presentation on Breast Cancer–Medcases
Dr. Vijay Anand P Reddy
13th July 2008
7:00–9:00
AM
Breakfast
9:00–12:30
Noon
Lung Cancer Session
Session Chairpersons
:
Dr. Ramakanth K Deshpande & Dr. Purvish M
Parikh
9:00–9:30 AM
:
Metastatic Lung Cancer-NSCLC Dr. Primo N
Lara Jr
• 31696 - Maintenance pemetrexed plus best supportive care (BSC) versus placebo
plus BSC: A phase III study
T. Ciuleanu, T. Brodowicz, C. Belani, J. Kim, M. Krzakowski, E. Laack, Y. Wu,
P. Peterson, S. Adachi, C. Zielinski
• 30338 - FLEX: A randomized, multicenter, phase III study of cetuximab in
combination with cisplatin/vinorelbine (CV) versus CV alone in the first-line
treatment of patients with advanced non-small-cell lung cancer (NSCLC)
R. Pirker, A. Szczesna, J. von Pawel, M. Krzakowski, R. Ramlau, K. Park, U.
Gatzemeier, E. Bajeta, M. Emig, J. Pereira
9:30–10:15 AM
:
Extensive Lung Cancer –SCLC Dr. Ashok Kumar
Vaid
• 35772-S0124: A randomized phase III trial comparing irinotecan/cisplatin (IP)
with etoposide/cisplatin (EP) in patients (pts) with previously untreated
extensive stage small cell lung cancer (E-SCLC)
R. B. Natale, P. N. Lara, K. Chansky, J. Crowley, J. R. Jett, J. E. Carleton,
J. P. Kuebler, H. Lenz, P. Mack, D. G. Gandara
• 30840-Topotecan/cisplatin (TP) compared to cisplatin/etoposide (PE) for
patients with extensive diseasesmall cell lung cancer (ED-SCLC): final results
of a randomised phase III trial
C. F. Heigener, L. Freitag, C. Eschbach, R. M. Huber, T. Fink, S. Hummler, N.
Banik, M. Wolf, ABC Study Group
10.15–10.45 AM
:
Discussion on Metastatic Lung Cancer
Moderator
Dr. (Col). Ranga Rao
Panelists
Dr. Atul Sharma
Dr. Tarini Prasad Sahoo
Dr. (Col). A.K. Dhar
10.45–11.00 AM
:
Tea Break
11.00–11:30 AM
:
Lung Cancer (Other than Chemotherapy)
Prof. D. Raghunadharao
• 32942 - Randomized trial of standard dose to a higher dose
prophylactic cranial irradiation (PCI) in limited-stage small cell cancer
(SCLC) complete responders (CR): Primary end-point analysis (PC199-01, IFCT
99-01, EORTC 22003-08004, RTOG 0212) B. Le Pechoux, M. Hatton, A. Kobierska, F.
Guichard, A. Dunant, S. Senan , R. Jones, R.Arriagada, A. Wolfson, On behalf of
PCI99 Intergroup investigators
• 32591 - A 15-gene expression signature prognostic for survival
and predictive for adjuvant chemotherapy benefit in JBR.10 patients M. S. Tsao,
C. Zhu, K. Ding, D. Strumpf, M. Pintilie, M. Meyerson, L. Seymour, I. Jurisica,
F. A.Shepherd
11.30–12.00 Noon
: Discussion
on Local- Regional Therapy and Adjuvant Therapy
Moderator
Dr. Govind Babu
Panelists
Dr. Kumar T Bhowmik
Dr. R.P. Baral
Dr. M.S. Bansali
12.00–12.45 PM
:
Case Presentation on Lung Cancer– Medcases
Dr. Govind Babu
12.45–1.00 PM
:
Thank You Note Dr. Purna Kurkure
1.00–2.00
PM
Lunch
|